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Upon the identification of anandamide (AEA) in the porcine brain, numerous studies
contributed to the current state of knowledge regarding all elements that form the
“endocannabinoid system (ECS).” How this complex system of receptors, ligands, and
enzymes is integrated in helping to regulate fundamental processes at level of central
nervous and peripheral systems and how its regulation and dysregulation might counteract
disturbances of such functions, is nowadays still under investigation. However, the
most recent advances on the physiological distribution and functional role of ECS
allowed the progress of various research tools aimed at the therapeutic exploitation
of endocannabinoid (eCB) signaling, as well as the development of novel drugs with
pharmacological advantages. Here, we shall briefly overview the metabolic and signal
transduction pathways of the main eCBs representatives, AEA, and 2-arachidonoylglycerol
(2-AG), and we will discuss the therapeutic potential of new ECS-oriented drugs.
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ENDOCANNABINOID SYSTEM: METABOLISM AND
TARGETS OF ENDOCANNABINOIDS
Starting from 1992, when anandamide (AEA) was identified
for the first time in the porcine brain (Devane et al., 1992),
numerous studies contributed to the current state of knowledge
regarding all elements that form the “endocannabinoid system
(ECS)” (Maccarrone et al., 2010). Endocannabinoids (eCBs) are
lipid mediators, isolated from brain and peripheral tissues that
include amides, esters, and ethers of long chain polyunsaturated
fatty acids; they mimic the action of 9-tetrahydrocannabinol
(THC) in different biological processes. Until now, the most
bioactive eCBs are anandamide (arachidonylethanolamide; AEA)
and 2-arachidonoylglycerol (2-AG), yet the eCBs family includes
also virodhamine, noladin ether, and N-arachidonoyldopamine
(NADA), besides homo-linolenylethanolamide (HEA), docosate-
traenylethanolamide (DEA), and other cognate compounds such
as palmitoylethanolamide (PEA) and oleoylethanolamide (OEA)
(Figure 1).
eCBs are released “on demand” from membrane phos-
pholipid precursors and, although AEA synthesis might be
due to several metabolic routes (Muccioli, 2010), N-acylpho-
sphatidylethanolamine-specific phospholipase D (NAPE-PLD) is
currently considered the major enzyme responsible for AEA
production (Okamoto et al., 2009), whereas a specific phos-
pholipase C followed by the activity of the sn-1-diacylglycerol
lipase (DAGL) is responsible for 2-AG synthesis (Ueda et al.,
2011). The cellular uptake from the extracellular to the intra-
cellular space is ascribed to a purported “endocannabinoid
membrane transporter (EMT)” that is likely to take up both
AEA and 2-AG. However, while there is wide experimental evi-
dence to support the concept that AEA transport across mem-
branes is protein-mediated, conclusive evidence of its molecular
identity is still lacking. Very recently, a partly truncated fatty
acid amide hydrolase-1 (FAAH-1) termed FAAH-1 like anan-
damide transporter (FLAT) has been reported in neural cells
(Fu et al., 2011). After re-uptake, the biological activity of eCBs
is ended by a FAAH, for AEA (McKinney and Cravatt, 2005),
and/or by a specific monoacylglycerol lipase (MAGL), for 2-
AG (Dinh et al., 2002). Additionally, other enzymes showing
“amidase signature,” such as FAAH-2 (Wei et al., 2006) and the
N-acylethanolamine-hydrolyzing acid amidase (NAAA) (Tsuboi
et al., 2005), which belongs to the choloylglycine hydrolase family,
might bind with low affinity and hydrolyse AEA to release arachi-
donic acid and ethanolamine. Also cyclooxygenase-2 (COX-2),
different lipoxygenase (LOX) isozymes and cytochrome P450 are
able to accept AEA and 2-AG as a substrate, leading to the biosyn-
thesis of prostaglandin-ethanolamides (Kozak et al., 2002) and
-glyceryl esters (Kozak et al., 2001), hydroxy-anandamides, and
hydroxyleicosatetraenoyl-glycerols (van der Stelt et al., 2002),
respectively. For a comprehensive review on alternative pathways
of eCBs see and Rouzer andMarnett (Rouzer andMarnett, 2011).
eCBs act principally through cannabinoid receptors, that include
type-1 and type-2 (CB1 and CB2) receptors; more recently, it has
been highlighted the ability of some CB and non-CB ligands to
bind also to GPR55 (Glucksmann and Weich, 1999; Wise and
Brown, 2001; Drmota et al., 2004; Pertwee, 2007; Ryberg et al.,
2007; Lauckner et al., 2008), thus suggesting that the latter pro-
tein might act as a novel “type-3 (CB3)” cannabinoid receptor
(Moriconi et al., 2010). CB receptors are members of the large
family of heptahelical G protein coupled receptors (GPCRs), acti-
vate Gi/o proteins (Pertwee et al., 2010). Anatomical studies have
revealed that these receptors display a highly divergent pattern
of distribution throughout the organism: CB1 mainly present in
the central nervous system (Herkenham et al., 1991) and, on the
other hand, CB2 mainly distributed in peripheral and immune
cells (Munro et al., 1993). This topographical dichotomy has been
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FIGURE 1 | Chemical structures of biologically active eCBs and of the eCB-like compounds.
FIGURE 2 | Schematic representation of the main elements that
constitute the endocannabinoid system. The synthesis of
N-arachidonoyl-ethanolamine (AEA) is due to the activity of a NAPE-specific
phospholipase D (NAPE-PLD), whereas a fatty acid amide hydrolase (FAAH) is
responsible for its intracellular degradation to ethanolamine (EtNH2) and
arachidonic acid (AA). 2-Arachidonoylglycerol (2-AG) is released from
membrane lipids through the activity of diacylglycerol lipase (DAGL), and it is
hydrolyzed by a cytosolic monoacylglycerol lipase (MAGL) that releases
glycerol and AA. A purported endocannabinoid membrane transporter (EMT)
clears AEA and 2-AG from the extracellular space, and takes them up into the
cell. Both AEA and 2-AG trigger several signal transduction pathways by
acting at their targets, CB1, CB2, GPR55, and nuclear PPARs. AEA, but not
2-AG, binds intracellularly also TRPV1, and thus it is also designated as a true
endovanilloid.
revised by a number of studies documenting the presence of CB1
in several non-neuronal cells and tissues (Gong et al., 2006), and
of CB2 in the brain stem (van Sickle et al., 2005) and in neuronal
cells upon exogenous insults (Viscomi et al., 2009). In addition,
the non-selective cationic channel type-1 vanilloid receptor (tran-
sient receptor potential vanilloid 1, TRPV1), usually activated by
capsaicin and by noxious stimuli-like heat and protons (Di Marzo
and De Petrocellis, 2010), is an alternative target for AEA, but not
for 2-AG. More recently, also nuclear receptors like the peroxi-
some proliferator-activated receptors (PPARs) have been added
to the list of eCBs targets, activated under physiological and
pathological conditions (Pistis andMelis, 2010). A schematic rep-
resentation of eCBs, their receptors, biosynthetic and catabolic
enzymes, as well as putative transporter, is depicted in Figure 2.
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eCBS AND THEIR SIGNAL TRANSDUCTION PATHWAYS
The signal transduction pathways coupled to CB, TRPV1, and
PPAR receptors are summarized in Table 1. Among the effects
elicited by eCBs by binding to CB receptors, we should recall
Ca2+ channels inhibition (including N-, P/Q-, and L-type chan-
nels), inhibition of adenylyl cyclase and subsequent decrease of
cAMP-dependent protein kinase, which leads to decreased phos-
phorylation of the K+ channels, regulation of ionic currents, acti-
vation of focal adhesion kinase, stimulation of mitogen-activated
protein kinase (MAPK) cascades (Pertwee, 2006), and specifically
ERK, p38MAPK cascades (Derkinderen et al., 2001; Gertsch et al.,
2004), and the stimulation of additional intracellular pathways
including the phosphatidylinositol 3-kinase (PI3K)/Akt pathway
through CB2 (Molina-Holgado et al., 2002).
Unlike CB2, CB1 receptors are associated to special mem-
brane microdomains, called “lipid rafts” (LR) that modulate
CB1-dependent signaling pathways. The functional relationship
between CB1 and LR is affected by cholesterol content; in par-
ticular, membrane cholesterol enrichment in both primary and
immortalized cell lines reduces the binding to CB1 and subse-
quent G-protein dependent signaling through adenylyl cyclase
and MAPK (Bari et al., 2005). Moreover, the disruption of LRs by
cholesterol depletion modifies AEA-induced endocytosis of CB1,
which apparently loses the capacity to be directed toward the
lysosomal compartment. Therefore, LRs, besides representing a
favorable platform to regulate CB1 signaling, might also represent
a cellular device for its intracellular trafficking (Sarnataro et al.,
2005; Dainese et al., 2007). The general model to explain the neu-
romodulatory actions of AEA involves the release of eCBs from
a postsynaptic neuron upon stimulation, then the back diffusion
to presynaptic terminals, where AEA activates CB1 receptors, thus
modulating neuronal membrane permeability to Ca2+ e K+ ions
and the activity of adenylyl cyclase. The final outcome is a mod-
ified action of neurotransmitters (Di Marzo and De Petrocellis,
2010).
Table 1 | Signal transduction pathways triggered by eCBs at different
target receptors.
Receptor Effect
CB1 and CB2 ↓ Adenylyl cyclase
↑ Focal adhesion kinase (FAK) and mitogen-activated
protein kinase (MAPK)
↑ ERK, p38 through CB1,and PI3K/Akt through CB2
↑ K+ channels
↓ Ca2+ channels
GPR55 ↑ Intracellular [Ca2+]
↑ RhoA, Rac, and Cdc42
↑ ERK phosphorylation
TRPV1 ↑ Intracellular [Ca2+]
↑ Caspases
↑ Cytochrome c release
↑ Mitochondrial uncoupling
↑ Pro-apoptotic kinases
PPARs ↑ ROS
↑ Tyrosine kinases
↑ Adiponectin and lipoprotein lipase
The activation of GPR55, the purported “CB3” cannabi-
noid receptor, has been linked to (1) intracellular Ca2+ increase
(Lauckner et al., 2008); (2) activation of the small GTPase pro-
teins RhoA, Rac, and Cdc42 (Ryberg et al., 2007; Henstridge
et al., 2009), and (3) ERK phosphorylation (Oka et al., 2007,
2009). Additionally, by triggering PPARs, eCBs exert a variety
of long-term effects via genomic mechanisms and rapid non-
genomic actions, which are opposite to those evoked by activation
of “classical” surface cannabinoid receptors (Pistis and Melis,
2010). As a consequence, PPARs activation affects several phys-
iological and pathological processes, such as lipid metabolism,
energy balance, and feeding behavior, neuroprotection, epilepsy,
circadian rhythms, inflammation, addiction, and cognitive func-
tions (Pistis and Melis, 2010). However, AEA can also act as a
modulator of other signaling pathways and, in fact, it has been
observed that muscarinic and glutamate receptors have allosteric
sites for AEA binding (Lanzafame et al., 2004). In this context,
it should be underlined that there are several findings show-
ing that eCBs modulate the signaling of several neuropeptides
and hormones (Manzanares et al., 1999; Beinfeld and Connolly,
2001; Ghozland et al., 2002). This highly complex network of
interactions is reflected in the multifaceted modulatory effects
of eCBs on the regulation of brain and behavioral functions
(López-Moreno et al., 2008).
PHYSIOLOGICAL ACTIONS OF ECS AND THERAPEUTIC
PERSPECTIVES
The presence of ECS in vertebrates, mammals, and humans
implies a role in several physiological processes, including
appetite, cancer, cardiovascular diseases, fertility, immune func-
tions, memory, neuroprotection, and pain modulation (Ligresti
et al., 2009; Maccarrone et al., 2010) (Figure 3).
In the last 10 years, it has become clear that a dysregula-
tion of ECS is connected to pathological conditions, and thus
its modulation through inhibition of metabolic pathways and/or
agonism or antagonism of its receptors has an enormous potential
for research and intervention in multiple areas of human health.
FIGURE 3 | The involvement of ECS in some pathophysiological
conditions.
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Therefore, based on the therapeutic potential of THC, known
since centuries as medicine for its palliative effects in several
pathologies, plant-derived cannabinoids, synthetic cannabinoids,
and eCBs have been tested as novel therapeutics in a wide range
of clinical trials.
The neuroprotective effect of eCBs might be mediated by
either CB1- or CB2-dependent mechanisms. Research studies
using cb−/−1 knock-out mice showed an increased mortality
rate and an increased infarct area in cerebral ischemia mod-
els (Parmentier-Batteur et al., 2002). It has been reported that
the administration of the CB1 synthetic agonist WIN 55.212–2
attenuated the neurological damage and reduced infarct size in
artery occlusion induced in rats (Nagayama et al., 1999), and
additionally it reduced the glial damage after hypoxic-ischemic
brain injury in preterm lambs (Alonso-Alconada et al., 2010). The
presence of CB2-positive cells in the brain during injury and in
inflammatory neurodegenerative disorders might provide a novel
strategy for cannabinoid-mediated intervention against stroke-
induced neurodegeneration, without the unwanted psychoactive
effects of CB1 receptor stimulation (Cunha et al., 2011). O-3853
and O-1966, two selective CB2 agonists, administrated 1 h before
transient middle cerebral artery occlusion, significantly decreased
the mobilization of white blood cells and their adherence to vas-
cular endothelial cells, reduced the infarct size, and improved
motor function after transient focal ischemia (Zhang et al., 2007,
2009).
According to these observations, pain management is prefer-
ably handled using CB2 agonists, such as HU-308 and AM-1241,
which display significant relief in inflammatory and neuropathic
pain models, without exhibiting central nervous system side
effects (Hanus et al., 1999; Yao et al., 2006). In this context, new
selective CB2 receptor modulators, designed byGlaxo Smith Kline
as derivatives of pyrimidinecarboxamide, have been tested as
good clinical candidates to treat inflammatory, acute, and chronic
pain (Giblin et al., 2007, 2009).
In the past, several reports documented that the selective
pharmacologic antagonism of the CB1 receptor improves lipid
abnormalities associated with obesity, as well as neurodegenera-
tive diseases and nicotine or alcohol dependence (Centonze et al.,
2007; Di Marzo, 2008). Following the good outcome obtained in
Table 2 | Chemical structures and therapeutic potential of some ECS-targeted molecules.
Chemical structure Compound ECS target Diseases References
PF-04457845 FAAH Pain, Osteoarthritis Ahn et al., 2011
URB 597 Anxiety, Cannabis dependence,
Hyperalgesia
Bortolato et al., 2007
SR141716A CB1 Eating disorder Christopoulou and Kiortsis, 2011
WIN 55.212–2 Ischemic stroke, Brain injury Nagayama et al., 1999;
Alonso-Alconada et al., 2010
N
O
N O
O
HU-308 CB2 Neuropathic pain Hanus et al., 1999
O
O
OH
GSK554418A Acute/chronic pain Giblin et al., 2009
Cl N
H
N
N
N
O
O
GW842166X Inflammatory pain Giblin et al., 2007
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various clinical trials, the best known CB1 blocker SR141617A,
also called rimonabant (and commercially known as Acomplia®)
was released on the worldwide market as anti-obesity drug, but
only few months later it was withdrawn because of increased rates
of depression, anxiety, and suicide among patients who received it
(Christopoulou and Kiortsis, 2011). In addition, further concerns
were raised considering the possible side effects of this weight
loss pill on the reproductive functions and human infertility (Bari
et al., 2011).
Alternative strategies to treat pain syndromes, such as neu-
ropathic pain, fibromyalgia, but also spontaneous abortion,
headache, psychiatric disorders, and neurodegenerative diseases,
are based on the enhacement of the eCB tone, through the inhi-
bition of eCBs-hydrolyzing enzymes (Lichtman and Chapman,
2001). The most promising FAAH inhibitor seems to be URB597
(also named KDS-4103), which has biochemical and behavioral
effects during both sub-acute and chronic treatments. In rodents,
once-daily dosing of URB597 for five weeks elicits antidepres-
sant effects in chronically stressed animals, without altering CB1
receptor mRNA levels (Bortolato et al., 2007). Pfizer and Vernalis
pharmaceutical companies focused on FAAH as main target to
design and develop new molecules (PF-04457845 and V158866,
respectively), that are being tested in clinical studies as potential
therapies for a range of pain disorders, including osteoarthritis
(Ahn et al., 2011). It is noteworthy that FAAH inhibitors, because
of their own pharmacological properties, are attractive reme-
dial also for cannabis dependence; in fact, they do not appear
to evoke tolerance following long-term administration, and they
do not display significant abuse liability (Clapper et al., 2009).
Table 2 reports some agonists, antagonists, and/or inhibitors of
ECS designed for the treatment of several pathological conditions.
CONCLUSION
Almost 20 years after the identification of AEA, all members of
ECS are nowadays considered intriguing targets for the devel-
opment of selective and specific compounds able to modulate
human pathophysiology. A deeper and more detailed under-
standing of proteins involved in eCBs metabolism and signal-
transduction pathways could help to design compounds that
might prolong the activity of eCBs in a time- and site-dependent
way, excluding undesired psychotropic effects, and to develop
transgenic mice, where different ECS elements can be knocked
down or knocked in, allowing innovative therapeutic strategies in
a vast panorama of pathologies.
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